| Title |
Topiramate add‐on for drug‐resistant partial epilepsy
|
|---|---|
| Published in |
Cochrane database of systematic reviews, February 2014
|
| DOI | 10.1002/14651858.cd001417.pub3 |
| Pubmed ID | |
| Authors |
Jennifer Pulman, Nathalie Jette, Jonathan Dykeman, Karla Hemming, Jane L Hutton, Anthony G Marson |
| Abstract |
The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies and up to 30% from clinical series (not population-based) develop drug-resistant epilepsy, especially those with partial onset seizures. In this review we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed in 1996, when used as an add-on treatment for drug-resistant partial epilepsy. This is an updated version of the original Cochrane review published in Issue 3, 1999. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Ireland | 1 | 1% |
| Unknown | 68 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 16% |
| Student > Master | 10 | 14% |
| Other | 8 | 11% |
| Researcher | 6 | 9% |
| Student > Postgraduate | 5 | 7% |
| Other | 17 | 24% |
| Unknown | 13 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 29 | 41% |
| Psychology | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Social Sciences | 3 | 4% |
| Economics, Econometrics and Finance | 2 | 3% |
| Other | 13 | 19% |
| Unknown | 16 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 June 2019.
All research outputs
#7,811,306
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#8,625
of 11,842 outputs
Outputs of similar age
#69,938
of 234,970 outputs
Outputs of similar age from Cochrane database of systematic reviews
#180
of 239 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,970 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 239 others from the same source and published within six weeks on either side of this one. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.